ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced that CEO Stephen C. Glover will speak at the 33rd Annual Oppenheimer Healthcare Conference held virtually from March 13-15, 2023. During the event, Glover will discuss the development status of their Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, aimed at treating renal diseases, and the inflammasome ASC inhibitor IC 100, targeting various CNS and inflammatory diseases. The conference aims to showcase ZyVersa's innovative product pipeline and potential for stockholder value. To learn more, a virtual one-on-one meeting with Glover can be arranged via the conference portal.
- None.
- None.
- CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for multiple CNS and other inflammatory diseases
WESTON, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announced today that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President will participate in a fireside chat at the 33rd Annual Oppenheimer Healthcare Conference to be held virtually March 13-15.
Details regarding ZyVersa’s fireside chat are as follows:
| Event: | 33rd Annual Oppenheimer Healthcare Conference | |
| Date: | Monday, March 13, 2023 | |
| Time: | 11:20 AM EST | |
| Location: | Virtual –Link | |
“As a newly traded company on Nasdaq under the ticker “ZVSA,” we are pleased to discuss ZyVersa’s potential to build stockholder value as we advance development of our two platform technologies,” stated Mr. Glover. “ZyVersa is currently advancing two product candidates, Cholesterol Efflux MediatorTM VAR 200 in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, and inflammasome ASC inhibitor IC 100 which blocks initiation and perpetuation of damaging inflammation associated with numerous inflammatory diseases.”
To learn more about ZyVersa and its differentiated product Pipeline, please request a virtual one-on-one meeting with Mr. Glover through the conference portal.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. ZyVersa’s focus is on patients with renal or inflammatory diseases who have significant unmet medical needs. The company’s development pipeline includes phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for treatment of rare kidney disease, focal segmental glomerulosclerosis (FSGS). Other potential indications for VAR 200 include Alport syndrome and diabetic kidney disease. ZyVersa’s development pipeline also includes novel inflammasome ASC inhibitor IC 100 to control damaging inflammation associated with a multitude of inflammatory diseases. IC 100 has potential to treat numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.
New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.
Corporate and IR Contact:
Karen Cashmere
Chief Commercial Officer
kcashmere@zyversa.com
786-251-9641
Media Contacts
Tiberend Strategic Advisors, Inc.
Casey McDonald
cmcdonald@tiberend.com
646-577-8520
Dave Schemelia
dschemelia@tiberend.com
609-468-9325
FAQ
What is the date and time of ZyVersa's presentation at the Oppenheimer Healthcare Conference?
What is the focus of ZyVersa's product candidates VAR 200 and IC 100?
How can I attend the Oppenheimer Healthcare Conference virtually?
What ticker symbol does ZyVersa Therapeutics trade under?
Who will discuss ZyVersa's development updates at the conference?
